| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8444991 | European Journal of Cancer | 2013 | 11 Pages |
Abstract
The combination chemotherapy as compared to gemcitabine alone significantly improves OS in advanced pancreatic cancer (APC). However, this advantage is marginal whereas the treatment-related toxicity is increased, suggesting the use of gemcitabine-based combination regimens only in selected patient populations. New prospective trials, based on translational approaches and innovative validated biomarkers, are eagerly awaited on this topic.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Domenico Ciliberto, Cirino Botta, Pierpaolo Correale, Marco Rossi, Michele Caraglia, Pierfrancesco Tassone, Pierosandro Tagliaferri,